CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The BRECISE project aims to validate next-generation sequencing-based biomarkers for prostate and bladder cancer using artificial intelligence. By overcoming technical challenges, it seeks to enhance personalized cancer treatment and improve patient outcomes through precise risk assessment.
BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies.
By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer bioma…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
PHILIPS ELECTRONICS NEDERLAND BV
Netherlands, Eindhoven
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
United Kingdom, CLYDEBANK
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, GENT
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Madrid
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
